Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.
Masaki Imai,Kiyoko Iwatsuki-Horimoto,Masato Hatta,Samantha Loeber,Peter Halfmann,Noriko Nakajima,Tokiko Watanabe,Michiko Ujie,Kenta Takahashi,Mutsumi Ito,Shinya Yamada,Shufang Fan,Shiho Chiba,Makoto Kuroda,Lizheng Guan,Kosuke Takada,Tammy Armbrust,Aaron Balogh,Yuri Furusawa,Moe Okuda,Hiroshi Ueki,Atsuhiro Yasuhara,Yuko Sakai-Tagawa,Tiago J. S. Lopes,Tiago J. S. Lopes,Maki Kiso,Seiya Yamayoshi,Noriko Kinoshita,Norio Ohmagari,Shin-ichiro Hattori,Makoto Takeda,Hiroaki Mitsuya,Florian Krammer,Tadaki Suzuki,Yoshihiro Kawaoka,Yoshihiro Kawaoka +35 more
Reads0
Chats0
TLDR
It is found that SARS-CoV-2 isolates replicate efficiently in the lungs of Syrian hamsters and cause severe pathological lesions in the lung of these animals similar to commonly reported imaging features of COVID-19 patients with pneumonia.Abstract:
At the end of 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was detected in Wuhan, China, that spread rapidly around the world, with severe consequences for human health and the global economy Here, we assessed the replicative ability and pathogenesis of SARS-CoV-2 isolates in Syrian hamsters SARS-CoV-2 isolates replicated efficiently in the lungs of hamsters, causing severe pathological lung lesions following intranasal infection In addition, microcomputed tomographic imaging revealed severe lung injury that shared characteristics with SARS-CoV-2-infected human lung, including severe, bilateral, peripherally distributed, multilobular ground glass opacity, and regions of lung consolidation SARS-CoV-2-infected hamsters mounted neutralizing antibody responses and were protected against subsequent rechallenge with SARS-CoV-2 Moreover, passive transfer of convalescent serum to naive hamsters efficiently suppressed the replication of the virus in the lungs even when the serum was administrated 2 d postinfection of the serum-treated hamsters Collectively, these findings demonstrate that this Syrian hamster model will be useful for understanding SARS-CoV-2 pathogenesis and testing vaccines and antiviral drugsread more
Citations
More filters
Journal ArticleDOI
Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy
Dennis Christensen,Charlotta Polacek,Daniel J. Sheward,Leo Hanke,Ainhoa Moliner-Morro,Gerald M. McInerney,Ben Murrell,Katrine Top Hartmann,H. E. Jensen,Gregers Jungersen,Kristin E. Engelhart Illigen,Louise Krag Isling,Rune Fledelius Jensen,Julia Sid Hansen,Ida Rosenkrands,Carlota Fernandez-Antunez,Santseharay Ramirez,Frank Follmann,Jens Bukh,Gabriel K. Pedersen +19 more
TL;DR: In this paper , a parenteral prime-intranasal boost regimen was used to elicit airway mucosal immune responses and evaluated this in a Syrian hamster model of virus transmission.
Journal ArticleDOI
SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract
Frederick Hansen,Kimberly Meade-White,Chad S. Clancy,Rebecca Rosenke,Atsushi Okumura,David W. Hawman,Friederike Feldmann,B Hajime Kaza,Michael A. Jarvis,Kyle Rosenke,H. Feldmann +10 more
TL;DR: In this article , the authors used the Syrian hamster SARS-CoV-2 model to assess reinfection with homologous WA1 and heterologous B.1.7 and B.351 variants over time.
Posted ContentDOI
Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization
Yunjeong Kim,Natasha N. Gaudreault,David A. Meekins,Krishani Dinali Perera,Dashzeveg Bold,Jessie D. Trujillo,Igor Morozov,Chester McDowell,Kyeong-Ok Chang,Juergen A. Richt +9 more
TL;DR: In this paper, the effect of mutations in the SARS-CoV-2 Spike protein (S) has been investigated in nine different animal species to gain insights into the effects of VOC mutations on viral entry and antibody neutralization capability.
Journal ArticleDOI
Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
Shiho Chiba,Maki Kiso,Noriko Nakajima,Shun Iida,Tadashi Maemura,Makoto Kuroda,Yuko Sato,Mutsumi Ito,Moe Okuda,Shinya Yamada,Kiyoko Iwatsuki-Horimoto,Tokiko Watanabe,Masaki Imai,Tammy Armbrust,Ralph S. Baric,Peter Halfmann,Tadaki Suzuki,Yoshihiro Kawaoka +17 more
TL;DR: Co-administration of favipiravir and the remdesivir metabolite GS-441524 more effectively blocked SARS-CoV-2 replication in the lungs of Syrian hamsters than either favipIRavir or GS- 441524 alone as part of a prophylactic or therapeutic regimen.
Posted ContentDOI
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants
Hyeseon Cho,Hyeseon Cho,Kristina Kay Gonzales-Wartz,Kristina Kay Gonzales-Wartz,Deli Huang,Meng Yuan,Mary E. Peterson,Mary E. Peterson,Janie Liang,Nathan Beutler,Jonathan L. Torres,Yu Cong,Elena Postnikova,Sandhya Bangaru,Chloe Adrienna Talana,Wei Shi,Eun Sung Yang,Yi Zhang,Kwanyee Leung,Lingshu Wang,Linghang Peng,Jeff Skinner,Shanping Li,Nicholas C. Wu,Hejun Liu,Cherrelle Dacon,Thomas Moyer,Melanie Cohen,Ming Zhao,F. Eun-Hyung Lee,Rona Singer Weinberg,Iyadh Douagi,Robin Gross,Connie S. Schmaljohn,Amarendra Pegu,John R. Mascola,Michael R. Holbrook,David Nemazee,Thomas F. Rogers,Thomas F. Rogers,Andrew B. Ward,Ian A. Wilson,Peter D. Crompton,Joshua Tan +43 more
TL;DR: In this article, bispecific antibodies targeting SARS-CoV-2 from plasmablasts and memory B cells of COVID-19 patients were identified and three most potent antibodies targeted distinct regions of the RBD.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
A Novel Coronavirus from Patients with Pneumonia in China, 2019.
Na Zhu,Dingyu Zhang,Wenling Wang,Xingwang Li,Bo Yang,Jingdong Song,Xiang Zhao,Baoying Huang,Weifeng Shi,Roujian Lu,Peihua Niu,Faxian Zhan,Xuejun Ma,Dayan Wang,Wenbo Xu,Wenbo Xu,Guizhen Wu,George F. Gao,Wenjie Tan +18 more
TL;DR: Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.
Journal ArticleDOI
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more
TL;DR: Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
Safiya Richardson,Safiya Richardson,Jamie S. Hirsch,Jamie S. Hirsch,Mangala Narasimhan,James M. Crawford,Thomas McGinn,Thomas McGinn,Karina W. Davidson,Karina W. Davidson,Douglas P. Barnaby,Douglas P. Barnaby,Lance B Becker,John Chelico,John Chelico,Stuart L. Cohen,Stuart L. Cohen,Jennifer Cookingham,Kevin Coppa,Michael A Diefenbach,Andrew J. Dominello,Joan Duer-Hefele,Louise Falzon,Jordan Gitlin,Negin Hajizadeh,Negin Hajizadeh,Tiffany G. Harvin,David Hirschwerk,Eun Ji Kim,Eun Ji Kim,Zachary Kozel,Lyndonna Marrast,Lyndonna Marrast,Jazmin N. Mogavero,Gabrielle A. Osorio,Michael Qiu,Theodoros P. Zanos +36 more
TL;DR: This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area and assesses outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death.
Related Papers (5)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more